BSX logo

BSX
Boston Scientific Corp.

7,274
Mkt Cap
$84.23B
Volume
5.34M
52W High
$109.50
52W Low
$52.52
PE Ratio
23.96
BSX Fundamentals
Price
$57.45
Prev Close
$57.15
Open
$57.65
50D MA
$61.83
Beta
0.60
Avg. Volume
17.83M
EPS (Annual)
$1.94
P/B
3.28
Rev/Employee
$340,237.29
$152,666.58
Loading...
Loading...
News
all
press releases
Why Is Boston Scientific (BSX) Down 13% Since Last Earnings Report?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
News Placeholder
More News
News Placeholder
ISRG's SP Platform: Early-Stage Growth or Next TAM Expansion Driver?
ISRG's SP platform sees Q1 2026 procedures jump 68%, with new approvals and tools raising a key question: TAM expansion or procedure shift?
News Placeholder
Boston Scientific Corporation (BSX) Fell Due to Weak Results
Boston Scientific Corporation (BSX) Fell Due to Weak Results...
News Placeholder
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum
ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans.
News Placeholder
Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target
Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target...
News Placeholder
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?
According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
News Placeholder
Company News for May 19, 2026
Companies In The Article Are:REGN,D,NEE,STX and BSX
News Placeholder
FRACTURE IDE trial of the Boston Scientific SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
FRACTURE IDE trial of the Boston Scientific SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints FRACTURE IDE trial of the Boston Scientific...
News Placeholder
Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years
read more...
News Placeholder
Boston Scientific Targets Growing Aortic Stenosis Market With $1.5 Billion Deal
Boston Scientific invested $1.5 billion in MiRus and secured an option to acquire its investigational SIEGEL TAVR system.read more...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available